Chromium and Insulin Resistance

Completed · Not applicable · Has a placebo group

Conditions studied: Insulin Resistance

In brief

Chromium is an essential nutrient for the maintenance of normal glucose tolerance and its deficiency causes insulin resistance. Chromium administration has also been shown in several studies to lower glucose and insulin levels in patients with type 2 diabetes. Accordingly, we propose to perform a placebo-controlled study of chromium picolinate administration in a cohort of non-obese, non-diabetic, insulin resistant subjects. These subjects will be randomized to 16 weeks of therapy with either 500 mcg twice a day of Chromium or placebo.

Key facts

Study ID

NCT00846248

Run by

University of California, San Francisco

People needed

75

Starts

2006-01-01

Expected to finish

2011-07-01

Last updated by the study team

2012-08-31

Who can join

Age: 20 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Not exercising regularly, healthy, non-diabetic.

You may not qualify if…

• Diabetes, heart disease, hepatitis, HIV, impaired glucose tolerance, abnormal liver enzymes, abnormal TSH levels, other abnormal lab values.

Where it is running

• UCSF — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.